Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Serine peptidase inhibitor Kazal-type 5 (None)
- Target
- None
- Molecular classification
- Serine protease inhibitor, Kazal-type inhibitor
01
Overview
Serine peptidase inhibitor Kazal-type 5 (SPINK5) encodes LEKTI, a multidomain protein primarily expressed in stratified epithelial tissues like the skin and thymus. LEKTI contains 15 inhibitory domains that regulate serine proteases involved in skin barrier formation, desquamation, and immune responses. Mutations in SPINK5 are associated with Netherton syndrome and increased risk for atopic disorders. It also acts as a tumor suppressor in some cancers.
- Other names
- SPINK5LEKTILympho-epithelial Kazal-type-related inhibitorSerine protease inhibitor, Kazal type 5ISK5_HUMANNETSVAKTI
02
Mechanism of action
Inhibition of serine proteases, particularly kallikreins (KLK5, KLK7, KLK14)
03
Biological functions
Protease inhibitionRegulation of desquamationSkin barrier maintenanceAnti-inflammatory protectionAntimicrobial protectionLymphocyte development
04
Disease associations
Netherton SyndromeAtopic DermatitisEczemaAllergiesAsthmaEsophageal Squamous Cell Carcinoma
05
Safety considerations
Dysregulation leading to inflammatory skin conditionsPotential for off-target effects due to broad protease inhibition
Beyond the preview
Go deeper on Serine peptidase inhibitor Kazal-type 5 (None).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Serine peptidase inhibitor Kazal-type 5 (None).